

AD_____

Award Number: DAMD17-03-1-0159

TITLE: Coactivator Requirements for Serm Action

PRINCIPAL INVESTIGATOR: Erika K. Keeton, Ph.D.

CONTRACTING ORGANIZATION: Dana-Farber Cancer Institute
Boston, MA 02115

REPORT DATE: June 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20051227 210

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY)

01-06-2005

2. REPORT TYPE

Annual Summary

3. DATES COVERED (From - To)

1 Jun 2004 - 31 May 2005

4. TITLE AND SUBTITLE

Coactivator Requirements for Serm Action

5a. CONTRACT NUMBER

5b. GRANT NUMBER

DAMD17-03-1-0159

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Erika K. Keeton, Ph.D.

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

E-Mail: Erika_keeton@dfci.harvard.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Dana-Farber Cancer Institute

Boston, MA 02115

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Abstract follows.

15. SUBJECT TERMS

Estrogen receptor, transcription, coactivators, corepressors, SERMs tamoxifen, N-CoR, SMRT, proliferation

16. SECURITY CLASSIFICATION OF:

a. REPORT

U

b. ABSTRACT

U

c. THIS PAGE

U

17. LIMITATION OF ABSTRACT

UU

18. NUMBER OF PAGES

24

19a. NAME OF RESPONSIBLE PERSON

19b. TELEPHONE NUMBER (include area code)

ABSTRACT

Estrogen receptor α (ER α) mediates the effects of estrogens in breast cancer development and growth via transcriptional regulation of target genes. Tamoxifen can antagonize ER α activity and has been used in breast cancer therapy. The molecular determinants of tamoxifen action are not completely understood, but the availability of ER coregulators is thought to play a role. Tamoxifen-bound ER α associates with nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) at certain target genes. To determine if these corepressors are required for tamoxifen-mediated repression, their expression levels were reduced by RNA interference and the effects on tamoxifen action in breast cancer cells were measured. Silencing both corepressors led to tamoxifen-stimulated cell cycle progression without activation of the *c-myc*, *cyclin D1*, or *SDF-1* genes, which play a role in estrogen-induced cell growth. By contrast, expression of X-box binding protein 1 (XBP-1) was markedly elevated upon silencing N-CoR and SMRT and treating with tamoxifen. These results indicate that N-CoR and SMRT may influence tamoxifen action on a subset of genes involved in ER α function and cell proliferation. These findings help to further elucidate mechanisms underlying tamoxifen action that may be relevant to understanding tamoxifen-stimulated tumor growth.

Table of Contents

Cover.....	
SF 298.....	
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusions.....	7
References.....	7
Appendix.....	10

Introduction

Estrogen receptor α (ER α) can mediate the effects of estrogens in breast cancer development and progression via transcriptional regulation of target genes. Tamoxifen can antagonize ER α action and has been widely used in the prevention or treatment of breast cancer (1). Tamoxifen is a selective estrogen receptor modulator (SERM) which functions as an agonist or antagonist depending on the target gene, cell or tissue. Tamoxifen agonism in endometrial cells or tamoxifen-resistant breast cancer cells can lead to tumor growth. The molecular determinants of tamoxifen action are not completely understood, but the availability or activity of ER α coregulators is thought to play a role. The purpose of this research is to determine how the ER α corepressors N-CoR and SMRT influence tamoxifen-bound ER α action. The findings will lead to a better understanding of mechanisms underlying SERM action and the development and progression of hormone-responsive tumors.

Body

Tamoxifen can act as an ER α antagonist by competing with estrogen for binding to the ligand binding domain (LBD) of the receptor and creating an alternative structural conformation that blocks the interaction of coactivators with the coincident activation function-2 (AF-2) domain. (2, 3) Instead, tamoxifen-bound ER α has been shown to interact with the corepressors referred to as nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) and associate with these corepressors and histone deacetylases at certain ER α target promoters (4-7). The corepressors N-CoR and SMRT were originally identified as components of a complex involved in repression associated with unliganded retinoic acid receptor (RAR) and thyroid hormone receptor (8, 9). Association of these corepressors with unliganded ER α has not been clearly demonstrated. Their physiological role in tamoxifen-mediated antagonism or repression of ER α transcriptional activity and the critical target genes have also not been fully defined.

Alterations in the levels of ER α coregulators such as SRC-1, SMRT or N-CoR have been shown to influence tamoxifen action in various cell lines (4, 10-12). In this regard, tamoxifen is antagonistic in wild-type mouse embryonic fibroblasts (MEFs), but agonistic in N-CoR $^{-/-}$ MEFs (13). Low levels of N-CoR have also been implicated in the acquisition of tamoxifen resistance. Most ER α -positive breast cancer patients treated with tamoxifen ultimately develop resistance, which leads to tamoxifen-stimulated tumor growth (14). The mechanisms by which resistance is acquired are not known, but one possible mechanism is the emergence of tamoxifen's agonistic abilities through changes in the levels of ER coregulators. In support of this hypothesis, low N-CoR mRNA expression has been associated with shorter relapse-free survival in ER α -positive breast cancer patients treated with tamoxifen (15).

The aim of the second task was to determine if reducing the levels of the corepressors N-CoR and SMRT would lead to changes in tamoxifen action in breast cancer cells. This would help to better understand if these corepressors are required for tamoxifen-mediated repression or antagonism and how the relative levels of ER α coregulators in a target tissue may influence the response to tamoxifen.

In the last report it was shown that N-CoR and SMRT expression was reduced at the mRNA and protein levels by at least 60 percent in MCF-7 breast cancer cells by RNA interference (RNAi) (Appended manuscript Fig. 1A-B). It was further demonstrated that silencing N-CoR and/or SMRT relieved constitutive repression by the retinoic acid receptor (manuscript Fig. 2).

This result helped to validate that N-CoR and SMRT were functionally silenced at the observed reduced levels of mRNA and protein expression. In addition, it was reported that silencing both N-CoR and SMRT led to tamoxifen-stimulated cell cycle progression suggesting that they play a role in tamoxifen-mediated repression of ER α activity (manuscript Fig. 5). However, tamoxifen did not become an agonist on the *c-myc*, *cyclin D1*, and *SDF-1* genes (manuscript Fig. 3A-C), which have been identified as targets of ER α action that can mediate the proliferative effects of estradiol (16-18). By contrast, expression of X-box binding protein 1 (*XBP-1*) was markedly elevated in tamoxifen treated cells in which N-CoR and SMRT had been silenced (manuscript Fig. 4). These findings indicate that N-CoR and SMRT could be involved in constitutive repression of the *XBP-1* gene. Also, co-silencing N-CoR and SMRT coupled with tamoxifen treatment can lead to changes in gene expression that may contribute to increased ER α action and cell proliferation.

To further these findings, whether XBP-1 could play a role in tamoxifen-stimulated cell cycle progression was investigated. This gene has been identified as an ER α target gene activated in response to estradiol treatment by microarray analysis and was found by serial analysis of gene expression (SAGE) to be highly expressed in cancerous mammary epithelial cells (19-21). XBP-1 is a basic region leucine zipper (bZIP) protein that is a member of the CREB/ATF (cAMP response element-binding protein/activating transcription factor) family of transcription factors (22). This protein has been shown to play a role in hepatocyte growth (23). In addition, XBP-1 can enhance ER α -dependent transcriptional activity in a ligand-independent manner and its expression was found to be high in ER α -positive breast tumors (24, 25). However, a role for XBP-1 in estradiol-stimulated proliferation has not been demonstrated.

To determine if XBP-1 function contributes to cell cycle progression stimulated by estradiol-bound ER α , which would indicate it could mediate the observed tamoxifen effect, the gene was silenced by RNAi and the effect on cell cycle entry was examined. Forty-eight hours after transfection of MCF-7 cells with siRNA oligonucleotide duplexes targeting XBP-1, RNA was isolated from cells for analysis by real-time RT-PCR or cells were treated with vehicle or 100nM 17 β -estradiol for 24 h. Treated cells were then harvested and fixed before staining with propidium iodide for DNA content. The results in Figure 1A show that XBP-1 was effectively silenced at the mRNA level. Figure 1B demonstrates that reducing *XBP-1* levels did not effect estradiol-stimulated cell cycle progression, indicated by no observed reduction in cells entering S, G2, and M phases, as compared with the siLuc control. Therefore, it was concluded that increased XBP-1 expression in cells deficient in N-CoR and SMRT and treated with tamoxifen is not linked to the observed increase in cell cycle progression.

Many of the ER α target genes known to mediate cellular proliferation were not stimulated by tamoxifen when N-CoR and SMRT were silenced. Therefore, to confirm that the tamoxifen-stimulated cell cycle progression was dependent on ER α , cell cycle entry experiments were repeated in the ER-negative cell line MDA-MB231. The results of immunoblot analysis using MDA-MB231 whole cell extracts isolated after transfection with siRNA oligonucleotide duplexes demonstrate that N-CoR and SMRT were effectively co-silenced in this cell line (manuscript Fig. 6A). These cells were treated with vehicle, 100nM 17 β -estradiol, 1 μ M tamoxifen, or 10nM epidermal growth factor (EGF) as a positive control for growth stimulation. An increase in cell cycle entry was observed only upon treatment with EGF when N-CoR and SMRT were silenced in the ER-negative cells, suggesting that the tamoxifen-stimulated proliferation was strictly dependent on ER α (manuscript Fig. 6B).

To investigate whether silencing N-CoR and SMRT allowed MCF-7 cells to become more sensitive to mitogens other than tamoxifen, the effect of silencing the corepressors on cell cycle entry in response to increasing doses of estradiol was examined. Cells in which N-CoR and SMRT were silenced were not more sensitive to estradiol. The EC₅₀ values were nearly similar for estradiol under control and co-silencing conditions and the cell cycle entry in response to different doses of estradiol was actually reduced overall when N-CoR and SMRT were silenced (manuscript Fig. 6C). Thus, cells in which N-CoR and SMRT are silenced demonstrate an increase in proliferation specifically upon treatment with tamoxifen and not a more generalized increased sensitivity to growth stimuli.

Based on the increased cell cycle progression stimulated by tamoxifen in breast cancer cells when N-CoR and SMRT were silenced it seemed likely that overexpression of the corepressors in endometrial cells in which tamoxifen is an agonist and stimulates proliferation would lead to inhibition of tamoxifen action. We wanted to test this hypothesis, as indicated in part b of the second task. However, the cell cycle entry stimulated by tamoxifen in the Ishikawa endometrial carcinoma cell line and other cell lines tested was not large enough to be able to reproducibly measure an effect of overexpressing the corepressors.

Treatment of MCF-7 cells with estradiol leads to a reduction in ER α protein levels that is dependent on the coactivator AIB1 (26). This effect is not seen upon tamoxifen treatment. This may be due to the blocking of coactivator interactions with the AF-2 domain when tamoxifen binds to ER α . We wanted to investigate if reducing N-CoR and SMRT interaction with tamoxifen-bound ER α would allow the receptor to get degraded by AIB1. Thus, part d of the third task was to test if ER stabilization by tamoxifen is prevented when N-CoR and SMRT are silenced and if subsequent coactivator interactions with tamoxifen-bound ER α lead to receptor degradation and increased transcriptional activity. Figure 2 demonstrates that ER α is degraded by estradiol under control and co-silencing conditions, but not degraded by tamoxifen even when N-CoR and SMRT are silenced. Therefore, N-CoR and SMRT do not appear to be essential for blocking interactions of tamoxifen-bound ER α with the coactivator AIB1.

Key Research Accomplishments

- Determined if the relative levels of the ER corepressors N-CoR and SMRT and coactivators in breast cancer cells influence the response to tamoxifen.
- Silenced N-CoR and SMRT by RNA interference and measured the effect on tamoxifen action in stimulating cell cycle entry and activating ER α target genes that may mediate proliferation.
- Found that tamoxifen stimulates breast cancer cell cycle progression when N-CoR and SMRT are silenced and that expression of *XBP-1* is elevated.
- Determined that *XBP-1* does not appear to play an essential role in estrogen receptor-mediated cell proliferation and thus presumably not tamoxifen-stimulated cell cycle progression.
- Found that tamoxifen-stimulated cell cycle progression when N-CoR and SMRT are silenced depends on ER α .
- Showed that reduced levels of N-CoR and SMRT do not make breast cancer cells more sensitive to estradiol.

- Found that silencing N-CoR and SMRT does not prevent stabilization of ER α by tamoxifen.

Reportable Outcomes

Manuscript

Keeton, EK and Brown, M. 2005. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor- α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. *Mol. Endocrinol.* 19:1543-1554.

Conclusions

The research accomplished thus far has demonstrated that reducing the expression of the ER corepressors N-CoR and SMRT can lead to tamoxifen-stimulated cell cycle progression in breast cancer cells. The pro-proliferative estradiol target genes *c-myc*, *cyclin D1* and *SDF-1* did not become activated, but the expression of *XBP-1* was found to be elevated to the level stimulated by estradiol when cells in which N-CoR and SMRT were silenced were treated with tamoxifen. These findings suggest that N-CoR and SMRT play a role in tamoxifen-mediated repression of cell growth through a subset of ER α target genes. Although the function of XBP-1 as an ER coactivator could increase ER α signaling and proliferation, we found that XBP-1 does not appear to be essential for estradiol-stimulated cell growth. Efforts to identify the target gene(s) responsible for the increased cell cycle entry are underway. As described in part a of the third task, microarray analysis will be performed to determine what genes may be expressed at a higher level when N-CoR and SMRT are silenced and cells are treated with tamoxifen. Activation of these target genes will be validated by real-time PCR analysis, their role in cell growth will be examined using siRNA experiments, and interaction with N-CoR and SMRT will be investigated using chromatin immunoprecipitation. Other corepressor roles in tamoxifen action will also be studied.

Determining how tamoxifen-stimulated proliferation is mediated when N-CoR and SMRT are silenced will help to elucidate mechanisms underlying tamoxifen-stimulated growth and/or tamoxifen-resistance. This may lead to the identification of additional therapeutic targets. This work will also help to further define the molecular determinants of SERM action to assist in the design of better SERMs for the treatment of breast cancer.

References:

1. Wickerham L 2002 Tamoxifen--an update on current data and where it can now be used. *Breast Cancer Res Treat* 75 Suppl 1:S7-12; discussion S33-5
2. Shiau AK, Barstad D, Loria PM, et al. 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95:927-37
3. Brzozowski AM, Pike AC, Dauter Z, et al. 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 389:753-8
4. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. *Science* 295:2465-8.
5. Yamamoto Y, Wada O, Suzawa M, et al. 2001 The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. *J Biol Chem* 276:42684-91.

6. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 103:843-52.
7. Webb P, Nguyen P, Kushner PJ 2003 Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. *J Biol Chem* 278:6912-20
8. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* 377:454-7
9. Horlein AJ, Naar AM, Heinzl T, et al. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor *Nature* 377:397-404
10. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. *Mol Endocrinol* 11:657-66
11. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol Endocrinol* 11:693-705
12. Lavinsky RM, Jepsen K, Heinzl T, et al. 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. *Proc Natl Acad Sci U S A* 95:2920-5
13. Jepsen K, Hermanson O, Onami TM, et al. 2000 Combinatorial roles of the nuclear receptor corepressor in transcription and development. *Cell* 102:753-63.
14. Dorssers LC, Van der Flier S, Brinkman A, et al. 2001 Tamoxifen resistance in breast cancer: elucidating mechanisms. *Drugs* 61:1721-33
15. Girault I, Lerebours F, Amarir S, et al. 2003 Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. *Clin Cancer Res* 9:1259-66
16. Hall JM, Korach KS 2003 Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. *Mol Endocrinol* 17:792-803
17. Prall OW, Rogan EM, Sutherland RL 1998 Estrogen regulation of cell cycle progression in breast cancer cells. *J Steroid Biochem Mol Biol* 65:169-74
18. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL 1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. *Mol Cell Biol* 18:4499-508
19. Wang DY, Fulthorpe R, Liss SN, Edwards EA 2004 Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. *Mol Endocrinol* 18:402-11
20. Porter DA, Krop IE, Nasser S, et al. 2001 A SAGE (serial analysis of gene expression) view of breast tumor progression. *Cancer Res* 61:5697-702
21. Finlin BS, Gau CL, Murphy GA, et al. 2001 RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. *J Biol Chem* 276:42259-67
22. Liou HC, Boothby MR, Finn PW, et al. 1990 A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. *Science* 247:1581-4
23. Reimold AM, Etkin A, Clauss I, et al. 2000 An essential role in liver development for transcription factor XBP-1. *Genes Dev* 14:152-7

24. Ding L, Yan J, Zhu J, et al. 2003 Ligand-independent activation of estrogen receptor alpha by XBP-1. *Nucleic Acids Res* 31:5266-74
25. Perou CM, Sorlie T, Eisen MB, et al. 2000 Molecular portraits of human breast tumours. *Nature* 406:747-52
26. Shao W, Keeton EK, McDonnell DP, Brown M. 2004 Coactivator AIB1 links estrogen receptor transcriptional activity and stability. *Proc. Natl. Acad. Sci.* 101:11599-11604




Figure 1. Effect of reducing *XBP-1* levels on estradiol-stimulated cell cycle entry. MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting *XBP-1* or luciferase as a non-specific control. **A**, Relative *XBP-1* mRNA levels 48 h after Transfection determined using real-time RT-PCR. **B**, Increase in cells in S, G2, and M phases. Cells were treated with vehicle or 17 β -estradiol for 24 h after transfection for 48 h. Cells were then harvested and fixed before staining with propidium iodide to analyze DNA content by flow cytometry.




Figure 2. Effect of Silencing N-CoR and SMRT on Stabilization of ER α by Tamoxifen. MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR and SMRT or luciferase as a non-specific control. After transfection for 48 h, cells were treated with vehicle (EtOH), 100nM 17 β -estradiol (E2) or 1 μ M 4-hydroxytamoxifen (4HT) for 16 h. Whole cell extracts were isolated and protein expression was analyzed by immunoblot analysis.

Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor- α and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT

Erika Krasnickas Keeton and Myles Brown

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115

Estrogen receptor α (ER α) mediates the effects of estrogens in breast cancer development and growth via transcriptional regulation of target genes. Tamoxifen can antagonize ER α activity and has been used in breast cancer therapy. Tamoxifen-bound ER α associates with nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) at certain target genes. Here we show the effects of reducing N-CoR and SMRT levels on the actions of estrogen and tamoxifen in breast cancer cells. Silencing both corepressors led to tamoxifen-stimulated cell cycle progression without activation of the ER α target genes *c-myc*, *cyclin D1*, or stromal

cell-derived factor 1, which play a role in estrogen-induced proliferation. By contrast, expression of X-box binding protein 1 was markedly elevated in tamoxifen-treated cells in which N-CoR and SMRT had been silenced. The gain in cell cycle entry seen with tamoxifen when N-CoR and SMRT were silenced was dependent on ER α and not observed upon treatment with estradiol or epidermal growth factor. These results suggest that N-CoR and SMRT play an active role in preventing tamoxifen from stimulating proliferation in breast cancer cells through repression of a subset of target genes involved in ER α function and cell proliferation. (*Molecular Endocrinology* 19: 1543–1554, 2005)

THE ESTROGEN RECEPTOR (ER) belongs to a superfamily of nuclear receptors that function as ligand-activated transcription factors (1). This receptor mediates the effects of estrogens, which include proliferation and differentiation in reproductive tissues and have been linked to the development and progression of breast cancer (2, 3). Estrogenic effects are mediated by two forms of the ER, α and β , although a role for ER β in breast cancer has not been clearly defined (4–6). Estrogens can stimulate cell growth through ER α -mediated transcriptional regulation of target genes involved in proliferation (7–9). Tamoxifen can antagonize ER α action and has been widely used in the prevention or treatment of breast cancer (10).

The ERs can modulate transcription by binding directly to estrogen response elements (EREs) in the promoter region of target genes or indirectly through

transcription factors such as AP1 (11). Transcriptional activation is mediated by two activation function (AF) domains, AF-1 and AF-2. The AF-1 domain is located in the N terminus of the receptor and has a ligand-independent function that can be enhanced by phosphorylation through the MAPK pathway (12). The AF-2 domain is located in the ligand binding domain (LBD) in the C terminus of the receptor and its function is ligand dependent. Transcriptional activation by ER α is associated with the ligand-dependent recruitment of several coactivators, including AIB1, GRIP1, SRC1, CBP/p300 and p/CAF, and subsequent histone acetylation (13).

Tamoxifen acts as an ER α antagonist by competing with estrogen for binding to the LBD of the receptor and creating an alternative structural conformation that blocks the interaction of coactivators with the AF-2 domain (14, 15). Instead, tamoxifen-bound ER α has been shown to interact with the corepressors referred to as nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) and associate with these corepressors and histone deacetylases at certain ER α target promoters (13, 16–18). However, tamoxifen can also act as an agonist, presumably through coactivator interactions involving the AF-1 domain, depending on the target gene, cell, or tissue (19–22). For example, whereas tamoxifen functions as an antagonist in breast cancer cells, it acts as a partial agonist in endometrial cells.

First Published Online March 31, 2005

Abbreviations: AF, Activation function; AtRA, all-*trans* retinoic acid; DMSO, dimethylsulfoxide; EGF, epidermal growth factor; ER, estrogen receptor; ERE, estrogen response element; LBD, ligand binding domain; N-CoR, nuclear receptor corepressor; RAR, retinoic acid receptor; RARE, retinoic acid response element; RNAi, RNA interference; SDF-1, stromal cell-derived factor 1; si, small interfering; SMRT, silencing mediator for retinoid and thyroid hormone receptors; SRC-1, steroid receptor coactivator 1; XBP-1, X-box binding protein 1.

Molecular Endocrinology is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

How tamoxifen functions as a selective ER modulator is not completely understood, but the availability of ER coregulators has been shown to influence tamoxifen action. It has been shown in various cell lines that overexpression of the coactivators SRC-1 or L7/SPA enhances or leads to tamoxifen-stimulated transcription (17, 23, 24). Conversely, overexpression of the corepressors N-CoR or SMRT or silencing SRC-1 expression by RNA interference (RNAi) represses the partial agonist activity of tamoxifen (17, 23, 24). In addition, microinjection of N-CoR antibodies into MCF-7 cells leads to activation of an ERE/lacZ reporter by tamoxifen (25). Furthermore, tamoxifen is antagonistic in wild-type mouse embryonic fibroblasts, but agonistic in N-CoR^{-/-} type mouse embryonic fibroblasts (26).

Low levels of N-CoR have also been implicated in the acquisition of tamoxifen resistance. Most ER α -positive breast cancer patients treated with tamoxifen ultimately develop resistance, which leads to tamoxifen-stimulated tumor growth (27). The mechanisms by which resistance is acquired are not known, but one possible mechanism is the emergence of tamoxifen's agonistic abilities through changes in the levels of ER coregulators. In support of this hypothesis, low N-CoR mRNA expression has been associated with shorter relapse-free survival in ER α -positive breast cancer patients treated with tamoxifen (28). Decreased N-CoR protein expression has also been correlated with acquired tamoxifen resistance in a mouse model of breast cancer (25). In an additional study, lower N-CoR mRNA expression levels were found in tumors from patients with recurrence compared with patients without recurrence (29).

The corepressors N-CoR and SMRT were originally identified as components of a complex involved in repression associated with unliganded retinoic acid receptor (RAR) and thyroid hormone receptor (30, 31). Association of these corepressors with unliganded ER has not been clearly demonstrated. Their physiological role in tamoxifen-mediated antagonism or repression of ER α transcriptional activity and the critical target genes have also not been fully defined.

In this study, we wanted to know whether reducing the levels of the corepressors N-CoR and SMRT would lead to changes in tamoxifen action in breast cancer cells. This would help to better understand whether these corepressors are required for tamoxifen-mediated repression and how the relative levels of ER coregulators in a target tissue may influence the response to tamoxifen. Therefore, we silenced N-CoR and SMRT separately or together using small interfering (si) RNAs and tested whether tamoxifen could now stimulate proliferation or function as an agonist on endogenous ER α target genes that mediate estrogen-induced cell growth in breast cancer cells. The loss of N-CoR and SMRT function was validated by an observed relief of constitutive repression by the RAR on a retinoic acid response element (RARE) reporter gene. We found that silencing both N-CoR and SMRT

led to tamoxifen-stimulated proliferation in MCF-7 cells, but not through activation of the *c-myc*, *cyclin D1*, or *SDF-1* genes. By contrast, expression of X-box binding protein 1 (*XBP-1*) was markedly elevated when cells in which N-CoR and SMRT had been silenced were treated with tamoxifen. The cell cycle progression stimulated by tamoxifen when N-CoR and SMRT were silenced was not observed in an ER-negative cell line and thus dependent on ER α . In addition, the gain in proliferation was specific to tamoxifen and not observed upon treatment with estradiol or epidermal growth factor (EGF). These results suggest that N-CoR and SMRT play a role in the antiproliferative action of tamoxifen in breast cancer cells through repression of a subset of target genes involved in ER α function and cell proliferation.

RESULTS

Silencing of N-CoR and SMRT by RNA Interference

To examine whether reducing N-CoR and SMRT function alters tamoxifen action in breast cancer cells, these corepressors were silenced separately or together using RNAi. MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR (siN-CoR), SMRT (siSMRT), or luciferase (siLuc) as a non-specific control. For cosilencing of N-CoR and SMRT both specific siRNAs were transfected simultaneously. Immunoblot analysis of whole-cell extracts prepared from cells 48 h after transfection of siRNA demonstrates that N-CoR and SMRT were efficiently silenced or cosilenced by at least 60% at the protein level when quantified relative to calnexin (Fig. 1A). To confirm equivalent and efficient silencing at the mRNA level under each silencing condition, RNA was isolated 48 h after transfection with siRNA oligonucleotides and the relative levels of N-CoR and SMRT mRNA were analyzed by quantitative real-time RT-PCR. The results of this analysis showed that N-CoR mRNA levels were consistently reduced by 75% when silenced separately or together with SMRT (Fig. 1B). The mRNA levels of SMRT were reduced by approximately 65% when SMRT was silenced separately or together with N-CoR. Surprisingly, N-CoR mRNA levels were reduced by about 25% by siSMRT, but this effect was not seen at the protein level (Fig. 1A). This was not due to significant homology in the target siRNA sequence and thus may be due to regulation at the transcriptional level.

Silencing N-CoR or SMRT Relieves Constitutive Repression by the RAR

To validate that N-CoR and SMRT were functionally silenced at the observed reduced levels of mRNA and protein expression, the effect of silencing the corepressors separately or together on constitutive repression of




Fig. 1. Silencing of N-CoR and SMRT Separately or Together

MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR (siNCoR), SMRT (siSMRT), both corepressors, or luciferase (siLuc) as a nonspecific control. A, Western blot analysis of proteins from whole-cell extracts prepared 48 h after transfection. B, RNA was isolated from cells 48 h after transfection and analyzed by quantitative real-time RT-PCR using primers for N-CoR or SMRT. Results shown are the average expression of N-CoR and SMRT mRNA (normalized to GAPDH) relative to in the siLuc control from four independent experiments (\pm SEM).

a RARE reporter gene by the RAR was investigated. For these experiments, the reporter constructs (RARE) β_2 tk-luciferase and pCMV β -galactosidase, which was used as a normalization control, were cotransfected with siRNA oligonucleotides targeting N-CoR, SMRT, or both into MCF-7 cells. A scrambled N-CoR target sequence (scrNCoR) was used as a nonspecific control. Cells were treated for 24 h with vehicle [dimethylsulfoxide (DMSO)] or 100 nM all-*trans* retinoic acid (AtRA) 48 h after transfection and cellular extracts were prepared for use in the measurement of luciferase and β -galactosidase activity. The reduced levels of N-CoR and SMRT protein expression before treatment were similar to those shown in Fig. 1A. We found that silencing N-CoR, SMRT, or both core-

pressors relieved constitutive repression on the RARE reporter gene in the absence of hormone 3.2-, 2.4-, or 3.3-fold, respectively, as compared with the scrNCoR vehicle-treated control (Fig. 2). These levels of activation were near the average seen in the AtRA-treated scrNCoR control, which was 4.2-fold. In addition, the activation of the RARE reporter gene upon treatment with AtRA was significantly elevated when both N-CoR and SMRT were silenced to an average of 10.7-fold as compared with the vehicle-treated scrNCoR control. The average AtRA-induced luciferase activity in cells with reduced levels of N-CoR and SMRT relative to the corresponding vehicle-treated control was 3.2-fold. Thus, the fold activation stimulated by the RAR when N-CoR and SMRT were silenced was not increased as compared with that of the scrNCoR control, but the overall activity was higher. This may be due to elevated basal levels of activation and these findings suggest that N-CoR and SMRT also play a role in modulating ligand-activated transcription by the RAR on the RARE reporter gene. Taken together, these results indicate that N-CoR and SMRT were functionally silenced.

Effects of Silencing N-CoR and SMRT on Tamoxifen Action at Pro-Proliferative ER α Target Genes

We next examined whether reducing the levels of N-CoR, SMRT, or both could convert tamoxifen into an agonist on endogenous ER α target genes that can stimulate cell growth. The *c-myc*, *cyclin D1*, and *SDF-1* genes have been identified as targets of ER α action that can mediate the proliferative effects of estradiol (7–9). We investigated the effects of silencing N-CoR and SMRT separately or together on tamoxifen action on these three genes in MCF-7 cells as compared with estradiol-stimulated activation as a positive control. Cells were transfected with siRNA oligonucleotides targeting N-CoR, SMRT, both corepressors, or luciferase as a nonspecific control. Forty-eight hours after transfection, cells were treated for various times with 100 nM 17 β -estradiol (estradiol) or 1 μ M 4-hydroxytamoxifen (tamoxifen) before RNA isolation and analysis of target gene induction by quantitative real-time RT-PCR.

Induction of *c-myc* by estradiol was maximal at 1 h and the levels of mRNA returned to near basal levels after 7 h, even though estradiol was present (Fig. 3A, *left panel*). Tamoxifen treatment did not lead to a significant gain in activation of *c-myc* when N-CoR, SMRT, or both were silenced as compared with the siLuc control (Fig. 3A, *right panel*). *Cyclin D1* mRNA levels induced by estradiol were maximal at 3 h and this target gene was also not significantly activated upon treatment with tamoxifen up to 7 h even under cosilencing conditions (Fig. 3B, *left and right panels*, respectively). Activation of *c-myc* and *cyclin D1* by estradiol was also not significantly altered under any of the silencing conditions (Fig. 3, A and B, *left panels*). There was no activation of *c-myc*




Fig. 2. Effect of Silencing N-CoR or SMRT on Constitutive Repression and Ligand-Activated Transcription by the RAR

MCF-7 cells were transfected with (RARE) β_2 tk-luciferase and pCMV β -galactosidase reporter plasmids and siRNA oligonucleotide duplexes targeting N-CoR, SMRT, or a scrambled N-CoR target sequence (scrNCoR) as a nonspecific control. Forty-eight hours after transfection, cells were treated for 24 h with vehicle (DMSO) or 100 nM ATRA. Cell lysates were then prepared and used to measure reporter activity. Results shown are the average fold induction of luciferase activity normalized to β -galactosidase activity relative to the scrNCoR vehicle-treated control from three independent experiments \pm SEM (**, $P \leq 0.001$; *, $P \leq 0.01$; *, $P \leq 0.05$).

or *cyclin D1* by tamoxifen after treatment for as long as 30 h (data not shown). These results suggest that N-CoR and SMRT are not required for tamoxifen-mediated repression of ER α on the *c-myc* and *cyclin D1* genes.

The *SDF-1* gene was strongly activated by estradiol and mRNA levels increased up to 8-fold after treatment for 30 h in MCF-7 cells transfected with siLuc (Fig. 3C, left panel). The maximum fold estradiol-induced *SDF-1* mRNA levels were similar under each silencing condition. The levels of *SDF-1* mRNA were slightly increased to about 1.5-fold in response to treatment with tamoxifen for 12, 18, 24, or 30 h in cells transfected with siLuc (Fig. 3C, right panel). The tamoxifen-stimulated fold induction of *SDF-1* was similar when N-CoR was silenced, but was slightly elevated to a maximum of 2.3-fold when SMRT or both SMRT and N-CoR were silenced as compared with the corresponding untreated controls. However, the overall relative mRNA levels were not significantly elevated under these conditions. These results suggest that N-CoR and SMRT are not essential for tamoxifen-mediated repression on the *SDF-1* gene.

XBP-1 has also been identified as an ER α target gene activated in response to estradiol treatment by microarray analysis and was found by serial analysis of gene expression to be highly expressed in cancerous mammary epithelial cells (32–35). *XBP-1* is a basic region leucine zipper protein that is a member of the CREBP/ATF family of transcription factors (36). Although a role for *XBP-1* in estradiol-stimulated proliferation has not been demonstrated, this

protein has been shown to play a role in hepatocyte growth and plasma cell differentiation (37, 38). In addition, *XBP-1* can enhance ER α -dependent transcriptional activity in a ligand-independent manner, and its expression was found to be high in ER α -positive breast tumors (39–45). Therefore, we wanted to investigate the effect of silencing N-CoR and SMRT on expression of the *XBP-1* gene in response to tamoxifen treatment in MCF-7 cells. Figure 4 (left panel) shows that *XBP-1* mRNA levels were increased in response to estradiol treatment for 3–30 h to a maximum of 5.8-fold in cells transfected with the siLuc control. Interestingly, silencing N-CoR and SMRT separately or together led to elevated basal expression of *XBP-1* mRNA to a maximum of 2-fold under cosilencing conditions (Fig. 4, left and right panels). This led to lower fold activation of *XBP-1* by estradiol when N-CoR and/or SMRT were silenced, although the absolute mRNA levels reached nearly the same maximum. In response to tamoxifen, the *XBP-1* mRNA levels increased to a maximum of 1.9-fold in cells transfected with siLuc (Fig. 4, right panel). The tamoxifen-stimulated fold induction *XBP-1* activation increased slightly when N-CoR, SMRT, or both were silenced to a maximum of 2.1-, 2.5-, or 2.6-fold, respectively, after treatment for 24 h, as compared with the corresponding untreated controls. More significantly, the absolute levels of *XBP-1* mRNA were elevated to 3-, 3.7-, or 5-fold upon tamoxifen treatment when N-CoR, SMRT, or both were silenced, respectively. Thus, the *XBP-1* gene was activated to about the estradiol-induced level by tamoxifen when N-CoR and




Fig. 3. Effect of Silencing N-CoR and SMRT on ER α -Mediated Transcriptional Activation of the *c-myc*, *cyclin D1*, and *SDF-1* Genes in Response to Estradiol or Tamoxifen Treatment

A–C, MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR, SMRT, both corepressors, or luciferase as a nonspecific control. Forty-eight hours after transfection, cells were treated for the indicated times with 100 nM 17 β -estradiol (estradiol), or 1 μ M 4-hydroxytamoxifen (tamoxifen). RNA was isolated and analyzed by quantitative real-time RT-PCR. Data shown are the average mRNA levels (normalized to GAPDH) relative to those in the untreated siLuc control calculated from at least three independent experiments. Error bars represent SEM.

SMRT were cosilenced. The above findings indicate that N-CoR and SMRT are involved in constitutive repression of the *XBP-1* gene. Also, cosilencing N-

CoR and SMRT, coupled with tamoxifen treatment, can lead to changes in gene expression that could contribute to increased ER α action.




Fig. 4. Effect of Silencing N-CoR and SMRT on ER α -Mediated Transcriptional Activation of the *XBP-1* Gene in Response to Estradiol or Tamoxifen Treatment

MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR, SMRT, both corepressors, or luciferase as a nonspecific control. Forty-eight hours after transfection, cells were treated for the indicated times with 100 nM 17 β -estradiol or 1 μ M 4-hydroxytamoxifen. RNA was isolated and analyzed by quantitative real-time RT-PCR. Data shown are the average mRNA levels (normalized to GAPDH) relative to those in the untreated siLuc control calculated from at least three independent experiments. Error bars represent SEM.

Silencing of Both N-CoR and SMRT Leads to Tamoxifen-Stimulated Cell Cycle Progression

We did not observe a change in tamoxifen-bound ER α action on the *c-myc*, *cyclin D1*, and *SDF-1* genes when the levels of N-CoR, SMRT, or both were reduced, but that did not rule out the possibility that N-CoR and SMRT are required for the antiproliferative action of tamoxifen in breast cancer cells. Therefore, we measured the change in entry of MCF-7 cells into the cell cycle upon treatment with tamoxifen when N-CoR and SMRT were silenced separately or together. Forty-eight hours after transfection, cells were treated with vehicle, 100 nM 17 β -estradiol, or 1 μ M 4-hydroxytamoxifen for 24 h. Cells were then harvested and fixed before staining with propidium iodide for DNA content. The results in Fig. 5A show that cosilencing N-CoR and SMRT led to proliferation upon treatment with tamoxifen, indicated by an average 5% increase in cells entering G2, S, and M phases. This finding suggests that N-CoR and SMRT play a role in preventing tamoxifen from stimulating proliferation in breast cancer cells. Interestingly, there was no significant increase in cell cycle entry upon treatment with tamoxifen when N-CoR and SMRT were silenced individually. Also, the tamoxifen-stimulated increase in cell cycle entry did not reach that stimulated by estradiol, which was an average of 17.3% in the control siLuc-transfected cells. These results indicate that in cells with reduced levels of N-CoR and SMRT that tamoxifen is a partial agonist for the stimulation of cell cycle progression.

To determine whether the pro-proliferative effects of tamoxifen when N-CoR and SMRT were silenced was

dependent on ER α , we repeated the cell cycle entry experiments in the ER-negative cell line MDA-MB231. The results of immunoblot analysis using MDA-MB231 whole-cell extracts isolated after transfection with siRNA oligonucleotide duplexes demonstrate that N-CoR and SMRT were effectively cosilenced in this cell line (Fig. 6A). These cells were treated as above or with 10 nM EGF as a positive control for growth stimulation. As expected, we observed an increase in cell cycle entry only upon treatment with EGF and not with estradiol or tamoxifen in these ER-negative cells. This was also the case when N-CoR and SMRT were silenced. These findings support the conclusion that tamoxifen-stimulated proliferation in the setting of N-CoR and SMRT silencing is strictly dependent on ER α and in addition that N-CoR and SMRT silencing does not have a general growth promoting effect (Fig. 6B).

To examine whether silencing N-CoR and SMRT allowed MCF-7 cells to become more sensitive to mitogens other than tamoxifen, we investigated the effect of silencing the corepressors on cell cycle entry in response to increasing doses of estradiol. Cells in which N-CoR and SMRT were silenced were not more sensitive to estradiol. The EC₅₀ values were similar for estradiol under control and cosilencing conditions, and the cell cycle entry in response to different doses of estradiol was actually reduced overall when N-CoR and SMRT were silenced (Fig. 6C). Thus, cells in which N-CoR and SMRT are silenced demonstrate an increase in proliferation specifically upon treatment with tamoxifen and not a more generalized increased sensitivity to growth stimuli.




Fig. 5. Effect of Silencing N-CoR and SMRT on Cell Cycle Entry and Growth in Response to Estradiol or Tamoxifen Treatment

MCF-7 cells were transfected with siRNA oligonucleotide duplexes targeting N-CoR, SMRT, both corepressors, or luciferase as a nonspecific control. Forty-eight hours after transfection, cells were treated with vehicle, 100 nM 17β -estradiol, or 1 μ M 4-hydroxytamoxifen. After treatment for 24 h, cells were harvested by trypsinization and fixed before staining with propidium iodide to analyze DNA content by flow cytometry. Results shown represent the average change in cells in G2, S, and M phases stimulated by estradiol or tamoxifen relative to the vehicle-treated control under each silencing condition. Data are from three independent experiments \pm SEM (*, $P \leq 0.05$).

DISCUSSION

In this study, we examined whether silencing N-CoR, SMRT, or both corepressors together using RNAi could alter the antagonistic profile of tamoxifen in breast cancer cells. We tested whether reducing the expression of N-CoR and/or SMRT would allow endogenous levels of ER coactivators to mediate tamoxifen agonism and whether N-CoR and SMRT are essential for tamoxifen-mediated repression. Most previous studies used simple ERE reporter genes to measure changes in tamoxifen action (23–26). We wanted to examine breast cancer cell proliferation and endogenous ER α target genes involved in estradiol-stimulated growth to better understand how tamoxifen may stimulate growth in certain tissues or in tamoxifen-resistant cells.

We have shown that the expression of N-CoR and SMRT was reduced by more than 60% at the level of mRNA and protein by siRNA oligonucleotide duplexes transfected into MCF-7 cells. These reduced levels of N-CoR and/or SMRT were sufficient to relieve constitutive repression by the RAR on a RARE reporter gene and led to a significant increase in retinoic acid-stimulated activation when both N-CoR and SMRT were silenced, suggesting that the corepressors were functionally silenced. A role for N-CoR in modulating both basal and ligand-activated transcription by the RAR has been previously demonstrated (46). We found that silencing N-CoR or SMRT individually did not lead to tamoxifen-stimulated proliferation in MCF-7 cells, but silencing both corepressors together led to a significant increase in cell cycle entry upon tamoxifen treatment. These findings suggest that N-CoR and SMRT play a role in tamoxifen-mediated repression of cell growth in breast cancer cells. The finding that silenc-

ing both N-CoR and SMRT is required to observe tamoxifen-stimulated proliferation suggests that these corepressors have redundant or overlapping roles at the relevant target gene(s) involved and compensate for one another when each is silenced separately. These results also suggest the possibility that overexpression of N-CoR and SMRT in a tamoxifen-sensitive cell line, such as endometrial cells, may partially inhibit the agonistic action of tamoxifen.

The increase in cell cycle entry when N-CoR and SMRT were silenced was specific to tamoxifen because we did not observe an increase in the sensitivity of MCF-7 cells to estradiol under cosilencing conditions. These findings suggest that N-CoR and SMRT play a more important role in tamoxifen-mediated repression than in basal repression or prevention of estradiol stimulation of ER α and that reducing the expression of these proteins does not have a general growth promoting effect. Interestingly, it appears that N-CoR and SMRT may be needed for the optimal response to estradiol.

Our analysis of ER α target genes that mediate estradiol-stimulated proliferation indicated that tamoxifen action on the *c-myc*, *cyclin D1*, and *SDF-1* genes was not significantly altered when N-CoR and/or SMRT were silenced. Therefore, changes in the expression of these genes are not responsible for the increased cell cycle progression, we observed in response to tamoxifen. In addition, these results indicate that N-CoR and SMRT are not required for tamoxifen-mediated repression of these target genes and imply that other ER coregulators likely play a more important role. This suggests that although the corepressors can be recruited to some of these target genes upon treatment with tamoxifen, presumably as part of a complex




Fig. 6. Effect of Silencing N-CoR and SMRT on Cell Cycle Entry in Response to Estradiol, Tamoxifen, or EGF Treatment in ER-Negative MDA-MB231 Cells or MCF-7 Cells

Cells were transfected with siRNA oligonucleotides targeting N-CoR and SMRT or luciferase as a nonspecific control. Forty-eight hours after transfection, whole-cell extracts were prepared or cells were treated for 24 h with ethanol, 17 β -estradiol, 4-hydroxytamoxifen, or EGF as shown. Cells were harvested by trypsinization and fixed before staining with propidium iodide to analyze DNA content by flow cytometry. A, Western blot analysis of proteins in whole-cell extracts from transfected MDA-MB231 cells. B, The average percent of cells in G₂, S, and M phases stimulated by ethanol, estradiol, tamoxifen, or EGF under each silencing condition in MDA-MB231 cells. C, Cell cycle entry in MCF-7 cells treated with increasing concentrations of 17 β -estradiol as shown. Curves and EC₅₀ values were generated using GraphPad Prism software. Data shown are representative of three independent experiments done in duplicate \pm SD.

of other accessory proteins, that they are not functionally required for repression. In addition, although we previously demonstrated that *c-myc* became partially responsive to tamoxifen upon overexpression of SRC-1 in breast cancer cells (17), we have shown in this study that the actions of ER coregulators are promoter specific. Thus, the balance between coactivator and corepressor expression levels and alterations in tamoxifen action may not exclusively affect the same promoters. Although the expression of known pro-proliferative ER α target genes was not increased by tamoxifen when N-CoR and SMRT were silenced, the effect of tamoxifen was dependent on the ER because the same effect was not seen in the ER-negative cell line MDA-MB231.

We found that *XBP-1* mRNA levels were elevated in cells in which N-CoR and SMRT were silenced and observed a further increase in gene expression when these cells were treated with tamoxifen. Thus, N-CoR and SMRT play a role in basal repression of this and likely other ER α target genes. Interestingly, *XBP-1* expression has been shown to be elevated 3-fold in MCF-7-derived tamoxifen-resistant cells as compared

with the parent cell line (47). It is intriguing to speculate that higher *XBP-1* levels may be correlated with lower N-CoR or SMRT levels in tamoxifen-resistant cells or tumors. A role for *XBP-1* in estradiol- or tamoxifen-mediated cell growth has not been demonstrated, however, so additional target genes are likely to play an important role in mediating the tamoxifen-stimulated growth that we observed. Further studies are needed to elucidate the role of *XBP-1* in estradiol or tamoxifen action and breast cancer. Nonetheless, *XBP-1* represents an endogenous gene involved in ER α function with increased expression when levels of N-CoR and/or SMRT are reduced and cells are treated with tamoxifen.

Our findings support those of previous studies suggesting that N-CoR and SMRT play a role in tamoxifen-bound ER α action and that the relative level of ER coregulators can influence the cellular response to tamoxifen. Overexpression of N-CoR or SMRT in various cell lines was shown to repress the partial agonist activity of tamoxifen, whereas loss or reduction of N-CoR expression led to tamoxifen-stimulated transcription or was associated with tamoxifen resistance

(23–26, 28, 29). Our results further these findings by showing that the functions of N-CoR and SMRT are promoter specific and influence tamoxifen action on an endogenous gene.

Our results also supplement previous findings by demonstrating that N-CoR and SMRT play a role in preventing tamoxifen from stimulating proliferation in breast cancer cells. These results are consistent with those of a study showing that tamoxifen enhances cell growth in MCF-7 cells stably expressing dominant-negative N-CoR (48). However, both of these findings are in contrast to those demonstrating that constitutively expressing a dominant-negative N-CoR in MCF-7 cells does not lead to tamoxifen-stimulated cell cycle entry or proliferation (49). Although we found that it was necessary to silence both N-CoR and SMRT to observe tamoxifen-stimulated cell cycle entry, the N-CoR dominant-negative consisting of a receptor interaction domain is expected to block SMRT interaction with tamoxifen-bound ER α as well due to the similarity between these domains in both corepressors. The results of these studies may vary because the dominant-negative N-CoR retains the ability to bind to ER α , which may still be able to influence the binding of other ER coregulators to the AF-1 and AF-2 domains of the receptor. Recent findings suggest that other coregulators may bind to tamoxifen-bound ER α in the AF-2 domain. A peptide was identified that recognizes a novel tamoxifen-induced binding surface of ER α within the LBD and replacement of T1F2 LXXLL receptor-interacting motifs with the peptide resulted in a tamoxifen-responsive coactivator (50).

Tamoxifen was not converted into a full agonist in the cell cycle entry assay when N-CoR and SMRT were both silenced in this study. This may be due to incomplete silencing of N-CoR and SMRT. However, it is likely that other ER coregulators and the target genes they regulate also play a role in tamoxifen-mediated repression of proliferation. Other ER corepressors such as REA, Smad4, or scaffold attachment factor B1 may influence tamoxifen action on the target genes involved (51–53). A role for additional ER corepressors in tamoxifen action has been suggested based on the finding that peptides containing a receptor interacting CoRNR box motif that differs from that found in N-CoR and SMRT interact with tamoxifen-bound ER α (54). In addition, the fact that tamoxifen does not induce recruitment of ER coactivators in breast cancer cells also plays a role in its partial agonism (14, 15, 17).

It is unclear how the tamoxifen-stimulated growth observed when N-CoR and SMRT were silenced is mediated. Microarray analysis of genes that become activated when N-CoR and SMRT are silenced and cells are treated with tamoxifen may help to identify potential target genes. It is possible that tamoxifen-stimulated proliferation is mediated via a pathway different from that stimulated by estradiol and that tamoxifen-specific target genes are involved. Defining the mechanism(s) by which tamoxifen-stimulated

breast cancer cell growth occurs will help to characterize the action of tamoxifen and perhaps other selective ER modulators, understand tamoxifen resistance, and identify additional therapeutic targets.

MATERIALS AND METHODS

RNAi

siRNA oligonucleotide duplexes (Dharmacon, Inc., Lafayette, CO) were used to silence N-CoR and SMRT. The target sequence for N-CoR, located in the 5' end of the protein, was 5'-AAGAAGGAUCCAGCAUUCGGA-3'. The target sequence for SMRT, located in the 3'UTR, was 5'-AAAGUCUAAACUGAGCUCGCA-3'. The sequence targeting luciferase as a nonspecific control was 5'-AACACUUACGCUGAGUACU-UCGA-3'. The scrambled N-CoR target sequence was 5'-AAGAAGGAUCCGCGCAUUCGGA-3'.

Cell Culture and Transfection

MCF-7 and MDA-MB231 cells were maintained in DMEM (Cellgro, Herndon, VA) with 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine, 5 μ g/ml insulin (Sigma, St. Louis, MO), and 100 U/ml penicillin-streptomycin. The day before transfection, 3.3×10^5 or 1.6×10^5 cells/well, respectively, were grown in six-well plates in phenol red-free DMEM (Invitrogen, Carlsbad, CA) supplemented with 5% charcoal/dextran-treated fetal bovine serum (Hyclone) and 2 mM L-glutamine. Cells were transfected with 60 nM each siRNA duplex using 4.5 μ l LipofectAMINE 2000 (Invitrogen) in 2.5 ml Opti-MEM (Invitrogen) for 4 h before resuspension in fresh seeding medium. Final siRNA concentrations were brought to 120 nM with nonspecific control siRNA to equal the cosilencing condition. Forty-eight hours after transfection, cells were treated as indicated and used in subsequent analyses.

Immunoblot Analysis

Whole-cell extracts were prepared from MCF-7 or MDA-MB231 cells 48 h after transfection with siRNA duplexes. Pelleted cells were resuspended in a buffer containing 10 mM HEPES (pH 7.9), 10% glycerol, 0.1 mM EDTA, 1 mM dithiothreitol, 1 \times complete protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN), 1.5 mM MgCl₂, 10 mM KCl and 0.1% Nonidet P-40, after which NaCl was added to a final concentration of 400 mM. Lysates were incubated on ice 25 min before centrifugation. Protein concentration was determined by Bradford assay using a Bio-Rad (Hercules, CA) protein assay reagent.

Proteins (70 μ g) were separated by SDS-PAGE on 4–15% Tris-HCl gradient gels (Bio-Rad) and transferred to polyvinylidene difluoride for 2.5 h in 25 mM Tris, 192 mM glycine buffer with 10% methanol at 400 mA. Immunoblotting was done with polyclonal antibodies against N-CoR (1:4000) and Calnexin (1:10,000) (Stressgen Biotechnologies, Victoria, British Columbia, Canada) or a monoclonal SMRT antibody (1:3000) or polyclonal SMRT α antibody (1:250) (Upstate, Lake Placid, NY) in Tris-buffered saline containing 2% nonfat dry milk. Incubation with primary antibody was followed by incubation with horseradish peroxidase-conjugated donkey antirabbit (Pierce, Rockford, IL) at 1:5000 or goat antimouse (Bio-Rad) at 1:2000. Detection was carried out using the Pierce Super-Signal West Pico chemiluminescent substrate followed by scanning and quantification using a Fluorchem 5500 chemiluminescence imager (Alpha Innotech Corp., San Leandro, CA).

Luciferase and β -Galactosidase Assays

MCF-7 cells were transfected with siRNA duplexes as described above except that 8×10^5 cells were plated in 6-cm dishes and 200 ng pCMV β -galactosidase (CLONTECH, Palo Alto, CA) and 400 ng (RARE β)₂tk-luciferase were included in the transfection with 9 μ l LipofectAMINE 2000. Forty-eight hours after transfection, cells were treated with vehicle (DMSO) or 100 nM all-*trans* retinoic acid for 24 h. Cell extracts were prepared using 400 μ l 1 \times Reporter Lysis Buffer (Promega, Madison, WI). Assays were performed with 25 μ l extract and the Promega luciferase assay system or Tropic Galacto-Star β -galactosidase reporter gene assay system (Applied Biosystems, Foster City, CA). Luciferase and β -galactosidase activity were detected using a Monolight 2010 luminometer. Luciferase activity was normalized to β -galactosidase activity.

Real-Time RT-PCR

Total RNA was isolated from transfected MCF-7 cells treated with 100 nM 17 β -estradiol (Sigma) or 1 μ M 4-hydroxytamoxifen (Sigma) using the RNeasy mini kit (QIAGEN, Valencia, CA), with on-column deoxyribonuclease treatment to remove contaminating genomic DNA. Real-time RT-PCR was performed using 25–200 ng RNA and 100–200 nM of the primers listed below with SYBR Green PCR Master Mix and MultiScribe reverse transcriptase (Applied Biosystems) according to the manufacturer's protocol. Sequence detection was performed using the ABI PRISM 7700. The following primer pairs were used: N-CoR, 5'-AGCATTCCATCCCTACGGG-3', sense, and 5'-TGGACCCCTTACCAAAGC-3', antisense; SMRT, 5'-CGCAACTGGTCGGCCA-3', sense, and 5'-GCTGCAAGATCTCATCGAGGT-3', antisense; myc, 5'-GCCACGTCTCCACACATCAG-3', sense, and 5'-TCTTGGCAGCAGATAGTCCTT-3', antisense; cyclin D1, 5'-TGGAGGTCTGCGAGGAACAGAA-3', sense, and 5'-TGCAAGCGGCTCTTTTCA-3', antisense; SDF-1, 5'-CCTGAGCTACAGATGCCCATG-3', sense, and 5'-TGAGATGCTTGACGTTGGCT-3', antisense; and XBP-1, 5'-GCGCCTCACGCACCTG-3', sense, and 5'-GCTGCTACTCTGTTTTTCAGTTTCC-3', antisense. The primers used to amplify GAPDH as a normalization control were: 5'-TCCACCCATGGCAAATTCC-3', sense, and 5'-TCGCCCCACTTGATTTTGG-3', antisense. Amplification of specific targets was verified by agarose gel electrophoresis and dissociation curve analysis.

Cell Cycle Entry Assay

For cell cycle entry analysis transfected MCF-7 or MDA-MB231 cells were treated with ethanol, 100 nM 17 β -estradiol, 1 μ M 4-hydroxytamoxifen, or 10 nM human recombinant EGF (Sigma) for 24 h before trypsinization, washing in PBS and fixation in 40% methanol. Fixed cells were treated with 200 μ l ribonuclease A (0.5 mg/ml) for 30 min at 37°C. Cells were then stained with an equal volume of propidium iodide (69 μ M in 38 mM sodium citrate, pH 7.4) for at least 1 h and analyzed for DNA content by flow cytometry by a core facility.

Acknowledgments

We thank Dr. Mitch Lazar for kindly providing the N-CoR and SMRT antibodies and for helpful discussion.

Received October 5, 2004. Accepted March 23, 2005.

Address all correspondence and requests for reprints to: Myles Brown, Department of Medical Oncology, Dana-Farber

Cancer Institute, 44 Binney Street, D730, Boston, Massachusetts 02115. E-mail: myles_brown@dfci.harvard.edu.

This work was supported in part by the Dana-Farber/Harvard Cancer Center Breast Cancer Specialized Program of Research Excellence Grant and by a Department of Defense Breast Cancer Research Program Award (DAMD17-03-1-0159) (to E.K.K.).

REFERENCES

- Evans RM 1988 The steroid and thyroid hormone receptor superfamily. *Science* 240:889–895
- Korach KS 1994 Insights from the study of animals lacking functional estrogen receptor. *Science* 266:1524–1527
- Henderson BE, Ross R, Bernstein L 1988 Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation award lecture. *Cancer Res* 48:246–253
- Enmark E, Gustafsson JA 1999 Oestrogen receptors—an overview. *J Intern Med* 246:133–138
- Speirs V 2002 Oestrogen receptor β in breast cancer: good, bad or still too early to tell? *J Pathol* 197:143–147
- Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA 2002 Estrogen receptor β in breast cancer. *Endocr Relat Cancer* 9:1–13
- Prall OW, Rogan EM, Sutherland RL 1998 Estrogen regulation of cell cycle progression in breast cancer cells. *J Steroid Biochem Mol Biol* 65:169–174
- Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL 1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. *Mol Cell Biol* 18:4499–4508
- Hall JM, Korach KS 2003 Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. *Mol Endocrinol* 17:792–803
- Wickerham L 2002 Tamoxifen—an update on current data and where it can now be used. *Breast Cancer Res Treat* 75(Suppl 1):S7–S12; discussion S33–S35
- Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. *J Steroid Biochem Mol Biol* 74:311–317
- Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270:1491–1494
- Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 103:843–852
- Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 389:753–758
- Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95:927–937
- Yamamoto Y, Wada O, Suzawa M, Yogiashi Y, Yano T, Kato S, Yanagisawa J 2001 The tamoxifen-responsive estrogen receptor α mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. *J Biol Chem* 276:42684–42691
- Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. *Science* 295:2465–2468
- Webb P, Nguyen P, Kushner PJ 2003 Differential SERM effects on corepressor binding dictate ER α activity in vivo. *J Biol Chem* 278:6912–6920
- Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type

- and promoter-context dependent agonistic activity of the anti-estrogen 4-hydroxytamoxifen. *EMBO J* 9:2811–2818
20. McInerney EM, Katzenellenbogen BS 1996 Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. *J Biol Chem* 271:24172–24178
 21. Metzger D, Losson R, Bornert JM, Lemoine Y, Chambon P 1992 Promoter specificity of the two transcriptional activation functions of the human oestrogen receptor in yeast. *Nucleic Acids Res* 20:2813–2817
 22. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. *Mol Endocrinol* 12:1605–1618
 23. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. *Mol Endocrinol* 11:657–666
 24. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol Endocrinol* 11:693–705
 25. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. *Proc Natl Acad Sci USA* 95:2920–2925
 26. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG 2000 Combinatorial roles of the nuclear receptor corepressor in transcription and development. *Cell* 102:753–763
 27. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA 2001 Tamoxifen resistance in breast cancer: elucidating mechanisms. *Drugs* 61:1721–1733
 28. Girault I, Lerebours F, Amar S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I 2003 Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. *Clin Cancer Res* 9:1259–1266
 29. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H 2000 Expression levels of estrogen receptor- α , estrogen receptor- β , coactivators, and corepressors in breast cancer. *Clin Cancer Res* 6:512–518
 30. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* 377:454–457
 31. Horlein AJ, Naar AM, Heinzel T, Torchia J, Glass B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* 377:397–404
 32. Wang DY, Fulthorpe R, Liss SN, Edwards EA 2004 Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. *Mol Endocrinol* 18:402–411
 33. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K 2001 A SAGE (serial analysis of gene expression) view of breast tumor progression. *Cancer Res* 61:5697–5702
 34. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynn R, Henderson MA, Armes JE, Venter DJ 2002 Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. *Cancer Res* 62:1289–1295
 35. Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM 2001 RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. *J Biol Chem* 276:42259–42267
 36. Liou HC, Boothby MR, Finn PW, Davidson R, Nabavi N, Zeleznik-Le NJ, Ting JP, Glimcher LH 1990 A new member of the leucine zipper class of proteins that binds to the HLA DR α promoter. *Science* 247:1581–1584
 37. Reimold AM, Etkin A, Clauss I, Perkins A, Friend DS, Zhang J, Horton HF, Scott A, Orkin SH, Byrne MC, Grusby MJ, Glimcher LH 2000 An essential role in liver development for transcription factor XBP-1. *Genes Dev* 14:152–157
 38. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravalles EM, Friend D, Grusby MJ, Alt F, Glimcher LH 2001 Plasma cell differentiation requires the transcription factor XBP-1. *Nature* 412:300–307
 39. Ding L, Yan J, Zhu J, Zhong H, Lu Q, Wang Z, Huang C, Ye Q 2003 Ligand-independent activation of estrogen receptor α by XBP-1. *Nucleic Acids Res* 31:5266–5274
 40. Bertucci F, Houlgatte R, Beniziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyen C 2000 Gene expression profiling of primary breast carcinomas using arrays of candidate genes. *Hum Mol Genet* 9:2981–2991
 41. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giaconia A, Beniziane A, Devillard E, Jacquemier J, Viens P, Nguyen C, Birnbaum D, Houlgatte R 2002 Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. *Hum Mol Genet* 11:863–872
 42. Iwao K, Matoba R, Ueno N, Ando A, Miyoshi Y, Matsubara K, Noguchi S, Kato K 2002 Molecular classification of primary breast tumors possessing distinct prognostic properties. *Hum Mol Genet* 11:199–206
 43. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D 2000 Molecular portraits of human breast tumours. *Nature* 406:747–752
 44. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH 2002 Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415:530–536
 45. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson Jr JA, Marks JR, Nevins JR 2001 Predicting the clinical status of human breast cancer by using gene expression profiles. *Proc Natl Acad Sci USA* 98:11462–11467
 46. Loinder K, Soderstrom M 2003 The nuclear receptor corepressor (N-CoR) modulates basal and activated transcription of genes controlled by retinoic acid. *J Steroid Biochem Mol Biol* 84:15–21
 47. Semfali A, Oliva J, Badia E, Pons M, Duchesne MJ 2004 Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells. *J Steroid Biochem Mol Biol* 88:247–259
 48. Fujita T, Kobayashi Y, Wada O, Tateishi Y, Kitada L, Yamamoto Y, Takashima H, Murayama A, Yano T, Baba T, Kato S, Kawabe Y, Yanagisawa J 2003 Full activation of estrogen receptor α activation function-1 induces proliferation of breast cancer cells. *J Biol Chem* 278:26704–26714
 49. Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK 2003 Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist

- activities of the tamoxifen-bound estrogen receptor. *Mol Endocrinol* 17:1543–1554
50. Heldring N, Nilsson M, Buehrer B, Treuter E, Gustafsson JA 2004 Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors. *Mol Cell Biol* 24:3445–3459
51. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z, Cao X 2003 Smad4 as a transcription corepressor for estrogen receptor α . *J Biol Chem* 278:15192–15200
52. Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV 2000 Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. *Mol Endocrinol* 14:369–381
53. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS 1999 An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. *Proc Natl Acad Sci USA* 96:6947–6952
54. Huang HJ, Norris JD, McDonnell DP 2002 Identification of a negative regulatory surface within estrogen receptor α provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. *Mol Endocrinol* 16:1778–1792



Molecular Endocrinology is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.